Moreover, the percentage of APOE genotypes in cognitively unimpaired people with neuropathological or biomarker evidence of preclinical AD, or the percentage of people who meet the criteria for mild cognitive impairment with or without biomarker evidence of AD, is not well established (discussed in [12]). This evidence concerns the gene APOE and Alzheimer disease.